Literature DB >> 12760067

DNA damage responses and chemosensitivity in the E mu-myc mouse lymphoma model.

C A Schmitt1, R R Wallace-Brodeur, C T Rosenthal, M E McCurrach, S W Lowe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 12760067     DOI： 10.1101/sqb.2000.65.499

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN： 0091-7451


× No keyword cloud information.
  9 in total

Review 1.  Cellular senescence in cancer treatment: friend or foe?

Authors:  Pascal Kahlem; Bernd Dörken; Clemens A Schmitt
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

2.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.

Authors:  Bonnie Huang; Wuhbet D Abraham; Yiran Zheng; Sandra C Bustamante López; Samantha S Luo; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

3.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

Authors:  Hans-Guido Wendel; Abba Malina; Zhen Zhao; Lars Zender; Scott C Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Authors:  Amanda K Frank; Julia I-Ju Leu; Yan Zhou; Karthik Devarajan; Tatiana Nedelko; Andres Klein-Szanto; Monica Hollstein; Maureen E Murphy
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

5.  The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.

Authors:  Monica Cardone; Ayten Kandilci; Cintia Carella; Jonas A Nilsson; Jennifer A Brennan; Sema Sirma; Ugur Ozbek; Kelli Boyd; John L Cleveland; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  miR-19 is a key oncogenic component of mir-17-92.

Authors:  Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

7.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

8.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Authors:  Sven Rottenberg; Anders O H Nygren; Marina Pajic; Fijs W B van Leeuwen; Ingrid van der Heijden; Koen van de Wetering; Xiaoling Liu; Karin E de Visser; Kenneth G Gilhuijs; Olaf van Tellingen; Jan P Schouten; Jos Jonkers; Piet Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

9.  Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Authors:  Lynsey Vaughan; Paul A Clarke; Karen Barker; Yvan Chanthery; Clay W Gustafson; Elizabeth Tucker; Jane Renshaw; Florence Raynaud; Xiaodun Li; Rosemary Burke; Yann Jamin; Simon P Robinson; Andrew Pearson; Michel Maira; William A Weiss; Paul Workman; Louis Chesler
Journal:  Oncotarget       Date:  2016-09-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.